Efficacy and safety of geptanolimab (GB226) for relapsed or refractory peripheral T cell lymphoma: an open-label phase 2 study (Gxplore-002)

BACKGROUND: Peripheral T cell lymphoma (PTCL) is a rare disease and recent approved drugs for relapsed/refractory (r/r) PTCL provided limited clinical benefit. We conducted this study to evaluate the efficacy and safety of geptanolimab (GB226), an anti-PD-1 antibody, in r/r PTCL patients. METHODS: W...

Descripción completa

Detalles Bibliográficos
Autores principales: Shi, Yuankai, Wu, Jianqiu, Wang, Zhen, Zhang, Liling, Wang, Zhao, Zhang, Mingzhi, Cen, Hong, Peng, Zhigang, Li, Yufu, Fan, Lei, Guo, Ye, Ma, Liping, Cui, Jie, Gao, Yuhuan, Yang, Haiyan, Zhang, Hongyu, Wang, Lin, Zhang, Weihua, Zhang, Huilai, Xie, Liping, Jiang, Ming, Zhou, Hui, Shuang, Yuerong, Su, Hang, Ke, Xiaoyan, Jin, Chuan, Du, Xin, Liu, Li, Xi, Yaming, Ge, Zheng, Feng, Ru, Zhang, Yang, Zhou, Shengyu, Xie, Fan, Wang, Qian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7802130/
https://www.ncbi.nlm.nih.gov/pubmed/33436023
http://dx.doi.org/10.1186/s13045-021-01033-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7802130/
https://www.ncbi.nlm.nih.gov/pubmed/33436023
http://dx.doi.org/10.1186/s13045-021-01033-1

Ejemplares similares